Asia Pacific

Europe, Middle East & Africa (EMEA)

Latin America

North America
  • Home
  • Congress & Events
  • Timing of Next-Generation Sequencing (NGS) Relative to First-Line Therapy in Lung Cancer: Insights from the Global WAYFIND-R Registry

Timing of Next-Generation Sequencing (NGS) Relative to First-Line Therapy in Lung Cancer: Insights from the Global WAYFIND-R Registry

WAYFIND-R is a global, multicentre, prospective pan-cancer registry collecting long-term data from patients diagnosed with a solid tumour profiled with next-generation sequencing (NGS). The poster presents insights about the timing of NGS relative to first-line therapy in lung cancer.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Send Via Email

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site Stay on Medically

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically